Differential pathogenetic mechanisms of mutations in helix 2 and helix 6 of rhodopsin.

BRET CSNB GPCR Molecular simulations Visual arrestin mini G protein

Journal

International journal of biological macromolecules
ISSN: 1879-0003
Titre abrégé: Int J Biol Macromol
Pays: Netherlands
ID NLM: 7909578

Informations de publication

Date de publication:
26 Aug 2024
Historique:
received: 24 07 2024
revised: 20 08 2024
accepted: 24 08 2024
medline: 31 8 2024
pubmed: 31 8 2024
entrez: 28 8 2024
Statut: aheadofprint

Résumé

Variants in rhodopsin (RHO) have been linked to autosomal dominant congenital stationary night blindness (adCSNB), which affects the ability to see in dim light, and the pathogenetic mechanism is still not well understood. In this study we report two novel RHO variants found in adCSNB families, p.W265R and p.A269V, that map in the sixth transmembrane domain of RHO protein. We applied in silico molecular simulation and in vitro biochemical and molecular studies to characterize the two new variants and compare the molecular determinants to two previously characterized adCSNB variants, p.G90D and p.T94I, that map in the second transmembrane domain of the RHO protein. We demonstrate that W265R and A269V cause constitutive activation of RHO with light-independent G protein coupling and impaired binding to arrestin. Differently, G90D and T94I are characterized by slow kinetics of RHO activation and deactivation. This study provides new evidence on the differential contribution of transmembrane α-helixes two and six to the interaction with intracellular transducers of RHO and mutations in these helixes result in a similar phenotype in patients but with distinct molecular effects.

Identifiants

pubmed: 39197629
pii: S0141-8130(24)05895-1
doi: 10.1016/j.ijbiomac.2024.135089
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

135089

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest Authors A.B., S.DA., A.F., C.Z., B.B., F.F., L.C., V.K., I.M. and G.M. declare they have no competing financial interests. Author V.M. is shareholder of the company Mireca Medicines.

Auteurs

Andrea Bighinati (A)

University of Modena and Reggio Emilia, Department of Life Sciences, via G. Campi 287, 41125 Modena, Italy.

Sara D'Alessandro (S)

University of Modena and Reggio Emilia, Department of Life Sciences, via G. Campi 287, 41125 Modena, Italy.

Angelo Felline (A)

University of Modena and Reggio Emilia, Department of Life Sciences, via G. Campi 287, 41125 Modena, Italy.

Christina Zeitz (C)

Sorbonne Université, INSERM, CNRS, Institut de la Vision, 17 rue Moreau, 75012 Paris, France.

Béatrice Bocquet (B)

INM, Univ Montpellier, INSERM, CHU Montpellier, 80 Av. Augustin Fliche, 34295 Montpellier, France.

Livio Casarini (L)

University of Modena and Reggio Emilia, Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, via P. Giardini, 1355, 41126 Baggiovara, Modena, Italy.

Vasiliki Kalatzis (V)

INM, Univ Montpellier, INSERM, 80 rue Augustin Fliche, 34091 Montpellier, France.

Isabelle Meunier (I)

INM, Univ Montpellier, INSERM, CHU Montpellier, 80 Av. Augustin Fliche, 34295 Montpellier, France.

Francesca Fanelli (F)

University of Modena and Reggio Emilia, Department of Life Sciences, via G. Campi 287, 41125 Modena, Italy. Electronic address: francesca.fanelli@unimore.it.

Gaël Manes (G)

INM, Univ Montpellier, INSERM, 80 rue Augustin Fliche, 34091 Montpellier, France. Electronic address: gael.manes@inserm.fr.

Valeria Marigo (V)

University of Modena and Reggio Emilia, Department of Life Sciences, via G. Campi 287, 41125 Modena, Italy. Electronic address: valeria.marigo@unimore.it.

Classifications MeSH